Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegylated Interferon +/- Ribavirin for Children With Hepatitis C.

Trial Profile

Pegylated Interferon +/- Ribavirin for Children With Hepatitis C.

Phase of Trial: Phase III

Latest Information Update: 27 Sep 2018

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms PEDS-C
  • Most Recent Events

    • 21 Mar 2013 Based on the results of this trial, Pegasys received EU approval for the treatment of chronic hepatitis C in children and adolescents aged ≥5 years, according to a Roche media release.
    • 02 Mar 2012 Results published in Hepatology.
    • 08 Nov 2011 Results from a longitudinal evaluation relating adiponectin levels to treatment presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top